Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma

Sato,Yu; Gonda,Kenji; Harada,Maiko; Tanisaka,Yuki; Arai,Shin; Mashimo,Yumi; Iwano,Hirotoshi; Sato,Hiroshi; Ryozawa,Shomei; Takahashi,Takao; Sakuramoto,Shinichi; Shibata,Masahiko

doi:10.3892/br.2017.924

Increased neutrophil-to-lymphocyte ratio is a novel marker for nutrition, inflammation and chemotherapy outcome in patients with locally advanced and metastatic esophageal squamous cell carcinoma

Authors:
- Yu Sato
- Kenji Gonda
- Maiko Harada
- Yuki Tanisaka
- Shin Arai
- Yumi Mashimo
- Hirotoshi Iwano
- Hiroshi Sato
- Shomei Ryozawa
- Takao Takahashi
- Shinichi Sakuramoto
- Masahiko Shibata
View Affiliations

Affiliations: Department of Surgery, Toho University Sakura Medical Center, Sakura, Chiba 285‑8741, Japan, Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan, Department of Gastroenterology, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan, Department of Surgery, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan, Department of Palliative Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama 350‑1298, Japan, Department of Advanced Cancer Immunotherapy, Fukushima Medical University, Fukushima, Fukushima 960‑1259, Japan
Published online on: June 7, 2017 https://doi.org/10.3892/br.2017.924
Pages: 79-84

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most common types of cancer, and its progression is strongly influenced by the presence of inflammation. Recently, there has been growing interest in the host inflammatory response, and increasing evidence has indicated that the neutrophil‑to‑lymphocyte ratio (NLR), a useful marker of systemic inflammation, may be an effective prognostic indicator in various types of malignant diseases. In the present study, 260 patients with ESCC were enrolled, including 110 who received chemoradiation therapy (CRT) involving irradiation and chemotherapy of 5‑fluorouracil and cisplatin, and 150 received chemotherapy using 5‑fluorouracil and cisplatin (FP). The patients of each group were both divided into two groups according to their NLR: High NLR (NLR>3.0) and low NLR (NLR≤3.0). Serum levels of prealbumin and retinol binding protein, which are nutritional parameters, were both significantly inversely correlated with NLR in patients treated with CRT, and patients treated with FP. Levels of CRP, a marker of inflammation, were significantly correlated with NLR, and stimulation indices, markers of immune reactions, were inversely correlated with NLR in both of CRT patients and FP patients. In patients treated with CRT, a partial response was significantly higher in patients with a low NLR and with progressive disease compared to those with a high NLR. In patients treated with FP, a partial response was also significantly higher in patients with a low NLR and with progressive disease compared to those with a high NLR. The overall survival of patients with CRT and FP were both significantly worse in patients with a high NLR than in those with a low NLR. NLR may serve as a useful marker of the tumor response, immune suppression, malnutrition and prognosis upon CRT or FP in patients with locally advanced or metastatic ESCC.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Sohda M and Kuwano H: Current status and future prospects for esophageal cancer treatment. Ann Thorac Cardiovasc Surg. 23:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
3	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
4	Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
5	Jaiswal M, LaRusso NF, Burgart LJ and Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 60:184–190. 2000.PubMed/NCBI
6	McMillan DC: The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev. 39:534–540. 2013. View Article : Google Scholar : PubMed/NCBI
7	Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F and Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tomita M, Shimizu T, Ayabe T, Yonei A and Onitsuka T: Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res. 31:2995–2998. 2011.PubMed/NCBI
9	Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R and Mauri FA: Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer. 110:1930–1935. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhang H, Zhang L, Zhu K, Shi B, Yin Y, Zhu J, Yue D, Zhang B and Wang C: Prognostic significance of combination of preoperative platelet count and neutrophil-lymphocyte ratio (COP-NLR) in patients with non-small cell lung cancer: Based on a large cohort study. PLoS One. 10:e01264962015. View Article : Google Scholar : PubMed/NCBI
11	Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K and Hirakawa K: The prognostic significance of a postoperative systemic inflammatory response in patients with colorectal cancer. World J Surg Oncol. 13:1942015. View Article : Google Scholar : PubMed/NCBI
12	Albayrak S, Zengin K, Tanik S, Atar M, Unal SH, Imamoglu MA and Gurdal M: Can the neutrophil-to-lymphocyte ratio be used to predict recurrence and progression of non-muscle-invasive bladder cancer? Kaohsiung J Med Sci. 32:327–333. 2016. View Article : Google Scholar : PubMed/NCBI
13	Dong YW, Shi YQ, He LW and Su PZ: Prognostic significance of neutrophil-to-lymphocyte ratio in rectal cancer: A meta-analysis. Onco Targets Ther. 9:3127–3134. 2016.PubMed/NCBI
14	Nakamura K, Nagasaka T, Nishida T, Haruma T, Ogawa C, Kusumoto T, Seki N and Hiramatsu Y: Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer. Oncol Lett. 11:3975–3981. 2016.PubMed/NCBI
15	Aino H, Sumie S, Niizeki T, Kuromatsu R, Tajiri N, Nakano M, Satani M, Okamura S, Shimose S, Miyahara K, et al: The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol. 5:83–88. 2016.PubMed/NCBI
16	Ding PR, An X, Zhang RX, Fang YJ, Li LR, Chen G, Wu XJ, Lu ZH, Lin JZ, Kong LH, et al: Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 25:1427–1433. 2010. View Article : Google Scholar : PubMed/NCBI
17	Jung MR, Park YK, Jeong O, Seon JW, Ryu SY, Kim DY and Kim YJ: Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol. 104:504–510. 2011. View Article : Google Scholar : PubMed/NCBI
18	Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner C, et al: Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 109:416–421. 2013. View Article : Google Scholar : PubMed/NCBI
19	Li Y, An J, Huang S, He J and Zhang J: Esophageal cancer-derived microvesicles induce regulatory B cells. Cell Biochem Funct. 33:308–313. 2015. View Article : Google Scholar : PubMed/NCBI
20	Gholamin M, Moaven O, Memar B, Farshchian M, Naseh H, Malekzadeh R, Sotoudeh M, Rajabi-Mashhadi MT, Forghani MN, Farrokhi F, et al: Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma. World J Surg. 33:1439–1445. 2009. View Article : Google Scholar : PubMed/NCBI
21	Chen MF, Chen PT, Chen WC, Lu MS, Lin PY and Lee KD: The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression. Oncotarget. 7:7913–7924. 2016.PubMed/NCBI
22	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI
23	McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 12:223–226. 2009. View Article : Google Scholar : PubMed/NCBI
24	Zahorec R: Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 102:5–14. 2001.PubMed/NCBI
25	Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, Nakatani K, Ishido K, Naruke A and Ryu T: Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res. 3:153–161. 2009.PubMed/NCBI
26	Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L and Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
27	Ishida K, Iizuka T, Ando N and Ide H: Phase II study of chemoradiotherapy for advanced squamous cell carcinoma of the thoracic esophagus: Nine Japanese institutions trial. Jpn J Clin Oncol. 26:310–315. 1996. View Article : Google Scholar : PubMed/NCBI
28	Finn OJ: Cancer immunology. N Engl J Med. 358:2704–2715. 2008. View Article : Google Scholar : PubMed/NCBI
29	Yoshimoto Y, Suzuki Y, Mimura K, Ando K, Oike T, Sato H, Okonogi N, Maruyama T, Izawa S, Noda SE, et al: Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One. 9:e925722014. View Article : Google Scholar : PubMed/NCBI
30	Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al: Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood. 114:589–595. 2009. View Article : Google Scholar : PubMed/NCBI
31	Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H and Nishimura T: Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: Its potentiation by combination with Th1 cell therapy. Cancer Res. 70:2697–2706. 2010. View Article : Google Scholar : PubMed/NCBI
32	Shibata M and Gonda K: Cachexia, immunological participation. In: Horizons in Cancer ResearchNova Science. Watanabe HS: Publishers Inc.; New York: pp. 19–32. 2015
33	Shibata M, Nezu T, Kanou H, Abe H, Takekawa M and Fukuzawa M: Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J Clin Gastroenterol. 34:416–420. 2002. View Article : Google Scholar : PubMed/NCBI
34	Shibata M, Nagata Y, Kimura T, Kanou H, Nezu T, Takekawa M and Fukuzawa M: Elevated serum concentration of interleukin-1 receptor antagonist (IL-1ra) is correlated to interleukin-6 and hypoalbuminemia in cachectic patients with colorectal cancer. Int J Clin Oncol. 5:116–120. 2000. View Article : Google Scholar
35	Shibata M and Takekawa M: Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer. Oncology. 56:54–58. 1999. View Article : Google Scholar : PubMed/NCBI
36	Ohki S, Shibata M, Gonda K, Machida T, Shimura T, Nakamura I, Ohtake T, Koyama Y, Suzuki S, Ohto H, et al: Circulating myeloid-derived suppressor cells are increased and correlated to immune suppression and hypoalbuminemia in patients with cancer. Oncol Rep. 28:453–458. 2012.PubMed/NCBI
37	Nakamura I, Shibata M, Gonda K, Yazawa T, Shimura T, Anazawa T, Suzuki S, Sakurai K, Koyama Y, Ohto H, et al: Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncol Lett. 5:1682–1686. 2013.PubMed/NCBI
38	Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, Murata K, Fujii H, Nakano T and Kono K: Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 72:3967–3976. 2012. View Article : Google Scholar : PubMed/NCBI
39	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
40	Yoshimoto Y, Kono K and Suzuki Y: Anti-tumor immune responses induced by radiotherapy. Fukushima J Med Sci. 61:13–22. 2015. View Article : Google Scholar : PubMed/NCBI
41	Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, et al: Molecular and translational classifications of DAMPs in immunologic cell death. Front Immunol. 6:5882015. View Article : Google Scholar : PubMed/NCBI
42	Wang RF and Wang HY: Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 27:11–37. 2017. View Article : Google Scholar : PubMed/NCBI